Comments
Loading...

Relay Therapeutics

RLAYNASDAQ
Logo brought to you by Benzinga Data
$6.23
0.294.88%
Pre-Market: 5:11 PM EDT
Q3 2024 Earnings were released on Wed Nov 6th, after the market close
Consensus Rating1
Buy
Highest Price Target1
$45.00
Lowest Price Target1
$16.00
Consensus Price Target1
$24.10

Relay Therapeutics (NASDAQ:RLAY) Stock, Analyst Ratings, Price Targets, Forecasts

Relay Therapeutics Inc has a consensus price target of $24.1 based on the ratings of 11 analysts. The high is $45 issued by Berenberg on February 1, 2022. The low is $16 issued by Jefferies on September 10, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and JMP Securities on November 8, 2024, October 14, 2024, and September 17, 2024, respectively. With an average price target of $20 between HC Wainwright & Co., HC Wainwright & Co., and JMP Securities, there's an implied 221.03% upside for Relay Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Aug
2
Sep
0
0
0
0
Oct
0
0
0
0
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
JMP Securities
Stifel
B of A Securities
JP Morgan

1calculated from analyst ratings

Analyst Ratings for Relay Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Relay Therapeutics (RLAY) stock?

A

The latest price target for Relay Therapeutics (NASDAQ:RLAY) was reported by HC Wainwright & Co. on November 8, 2024. The analyst firm set a price target for $20.00 expecting RLAY to rise to within 12 months (a possible 221.03% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Relay Therapeutics (RLAY)?

A

The latest analyst rating for Relay Therapeutics (NASDAQ:RLAY) was provided by HC Wainwright & Co., and Relay Therapeutics maintained their buy rating.

Q

When was the last upgrade for Relay Therapeutics (RLAY)?

A

The last upgrade for Relay Therapeutics Inc happened on September 10, 2024 when Jefferies raised their price target to $16. Jefferies previously had a hold for Relay Therapeutics Inc.

Q

When was the last downgrade for Relay Therapeutics (RLAY)?

A

The last downgrade for Relay Therapeutics Inc happened on September 10, 2024 when Oppenheimer changed their price target from N/A to N/A for Relay Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

Q

Is the Analyst Rating Relay Therapeutics (RLAY) correct?

A

While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $19.00 to $20.00. The current price Relay Therapeutics (RLAY) is trading at is $6.23, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch